Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000724185 | SCV000227245 | pathogenic | not provided | 2014-08-26 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000175709 | SCV000790871 | likely pathogenic | Maple syrup urine disease | 2018-05-30 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000175709 | SCV002033194 | pathogenic | Maple syrup urine disease | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000175709 | SCV003249080 | pathogenic | Maple syrup urine disease | 2024-10-15 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Tyr42*) in the DBT gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in DBT are known to be pathogenic (PMID: 16579849, 16786533). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with DBT-related conditions. ClinVar contains an entry for this variant (Variation ID: 195157). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. For these reasons, this variant has been classified as Pathogenic. |